Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | HRH1 | P35367 | 1/20 | 0.87 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL7139430 | 1.00 | MEN1 (0.87) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL1893948 | 0.98 | MEN1 (0.84) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL677128 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL118455 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL28017793 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL69781 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL951660 | 0.91 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL9300885 | 0.91 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL4378230 | 0.91 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1SLC22A16 | |
| Acetylcarnitine SCHEMBL387375 | 0.91 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1SLC22A16 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130325-A1 | SERUM METABOLITES AS BIOMARKERS FOR CARNITINE TREATMENT OF SEPSIS | THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER | 2023-04-27 | — | — | US | disclosed |
| WO-2021202608-A1 | SERUM METABOLITES AS BIOMARKERS FOR CARNITINE TREATMENT OF SEPSIS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-07 | — | — | WO | disclosed |
| US-10330685-B2 | Markers for sepsis treatment | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-25 | — | — | US | disclosed |
| EP-2729491-B1 | BIOLOGICAL METHODS FOR PREPARING A FATTY DICARBOXYLIC ACID | RADICI CHIMICA S P A (IT) | 2019-05-08 | — | — | EP | disclosed |
| US-20170247709-A1 | EUKARYOTIC ORGANISMS AND METHODS FOR INCREASING THE AVAILABILITY OF CYTOSOLIC ACETYL-COA, AND FOR PRODUCING 1,3-BUTANEDIOL | GENOMATICA, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170052192-A1 | MARKERS FOR SEPSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-02-23 | — | — | US | disclosed |
| EP-2935563-A2 | BIOLOGICAL METHODS FOR PREPARING A FATTY DICARBOXYLIC ACID | Verdezyne, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140322779-A1 | EUKARYOTIC ORGANISMS AND METHODS FOR INCREASING THE AVAILABILITY OF CYTOSOLIC ACETYL-COA, AND FOR THE PRODUCING 1,3-BUTANEDIOL | GENOMATICA, INC. | 2014-10-30 | — | — | US | disclosed |
| WO-2014100461-A2 | BIOLOGICAL METHODS FOR PREPARING A FATTY DICARBOXYLIC ACID | VERDEZYNE, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013071226-A1 | EUKARYOTIC ORGANISMS AND METHODS FOR INCREASING THE AVAILABILITY OF CYTOSOLIC ACETYL-COA, AND FOR PRODUCING 1,3-BUTANEDIOL | GENOMATICA, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-6335361-B1 | Method of treating benign forgetfulness | JUVENON INC. | 2002-01-01 | — | — | US | disclosed |
| US-20010043983-A1 | Nutritional supplements for aged pets | HAMILTON NATHAN D (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1039894-B1 | COMPOSITIONS FOR INCREASING THE CONCENTRATION AND/OR MOTILITY OF SPERMATOZOA IN HUMANS | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2001-10-17 | — | — | EP | disclosed |
| US-20010018455-A1 | Medicament and therapeutical method for treating idiopathic asthenozoospermia | SIGMA-TAU HEALTHSCIENCE, S.P.A. (IT) | 2001-08-30 | — | — | US | disclosed |
| WO-2001058271-A1 | NUTRITIONAL SUPPLEMENTS FOR AGED PETS | JUVENON, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6235784-B1 | SEXUAL DISORDERS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2001-05-22 | — | — | US | disclosed |
| WO-2001032168-A1 | METHOD OF TREATING BENIGN FORGETFULNESS | JUVENON, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2001021208-A1 | NUTRITIONAL SUPPLEMENT FOR INCREASED ENERGY AND STAMINA | JUVENON CORPORATION (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6090848-A | SYNERGISTIC MIXTURE OF CARNITINE AND ACETYLCARNITINE | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2000-07-18 | — | — | US | disclosed |
| US-5863940-A | Medicament and therapeutical method for treating idiopathic asthenozoospermia | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1999-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10330685-B2 | Markers for sepsis treatment | CPT2, SLC25A20, CRAT | MEN1 4760/4885KMT2A 2914/4885CYP1A2 3573/4885 |
| US-20170052192-A1 | MARKERS FOR SEPSIS TREATMENT | CPT2, SLC25A20, CRAT | MEN1 4760/4885KMT2A 2914/4885CYP1A2 3573/4885 |
| US-20230130325-A1 | SERUM METABOLITES AS BIOMARKERS FOR CARNITINE TREATMENT OF SEPSIS | CPT2, SLC25A20, CRAT | MEN1 4445/4885KMT2A 1455/4885CYP1A2 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.